Cutia Therapeutics (HKG: 2487), a company specializing in dermatological treatments, has announced that the National Medical Products Administration (NMPA) has accepted for review its New Drug Application (NDA) for CU-30101, a topical lidocaine and tetracaine cream. This pharmaceutical product is designed to provide rapid and long-lasting anesthetic effects, leveraging the unique pharmacokinetic properties of its components.
CU-30101 combines the rapid dispersal of lidocaine with the long-acting effects of tetracaine, an amino acid ester local anesthetic that is more lipophilic and can concentrate in the epidermal stratum corneum. According to public data, while Taro Pharmaceuticals’ Pliaglis, which contains a similar lidocaine and tetracaine combination, is available globally, there is currently no equivalent product approved in China.- Flcube.com
